Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
519 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Stroke - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2016, provides an overview of the Stroke (Cardiovascular) pipeline landscape. Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 10, 21, 14, 1, 89 and 11 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 35 and 4 molecules, respectively.Stroke. Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Stroke Overview 8 Therapeutics Development 9 Stroke - Therapeutics under Development by Companies 11 Stroke - Therapeutics under Investigation by Universities/Institutes 19 Stroke - Pipeline Products Glance 21 Stroke - Products under Development by Companies 24 Stroke - Products under Investigation by Universities/Institutes 33 Stroke - Companies Involved in Therapeutics Development 36 Stroke - Therapeutics Assessment 128 Drug Profiles 145 Stroke - Dormant Projects 466 Stroke - Discontinued Products 481 Stroke - Product Development Milestones 485 Appendix 498
List of Tables
Number of Products under Development for Stroke, H2 2016 29 Number of Products under Development for Stroke - Comparative Analysis, H2 2016 30 Number of Products under Development by Companies, H2 2016 31 Number of Products under Development by Companies, H2 2016 (Contd..1) 32 Number of Products under Development by Companies, H2 2016 (Contd..2) 33 Number of Products under Development by Companies, H2 2016 (Contd..3) 34 Number of Products under Development by Companies, H2 2016 (Contd..4) 35 Number of Products under Development by Companies, H2 2016 (Contd..5) 36 Number of Products under Development by Companies, H2 2016 (Contd..6) 37 Number of Products under Development by Companies, H2 2016 (Contd..7) 38 Number of Products under Investigation by Universities/Institutes, H2 2016 39 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40 Comparative Analysis by Late Stage Development, H2 2016 41 Comparative Analysis by Clinical Stage Development, H2 2016 42 Comparative Analysis by Early Stage Development, H2 2016 43 Products under Development by Companies, H2 2016 44 Products under Development by Companies, H2 2016 (Contd..1) 45 Products under Development by Companies, H2 2016 (Contd..2) 46 Products under Development by Companies, H2 2016 (Contd..3) 47 Products under Development by Companies, H2 2016 (Contd..4) 48 Products under Development by Companies, H2 2016 (Contd..5) 49 Products under Development by Companies, H2 2016 (Contd..6) 50 Products under Development by Companies, H2 2016 (Contd..7) 51 Products under Development by Companies, H2 2016 (Contd..8) 52 Products under Investigation by Universities/Institutes, H2 2016 53 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 54 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 55 Stroke - Pipeline by AB Science SA, H2 2016 56 Stroke - Pipeline by Acticor Biotech, H2 2016 57 Stroke - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2016 58 Stroke - Pipeline by Addex Therapeutics Ltd, H2 2016 59 Stroke - Pipeline by advanceCor GmbH, H2 2016 60 Stroke - Pipeline by Affibody AB, H2 2016 61 Stroke - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 62 Stroke - Pipeline by Anavex Life Sciences Corp, H2 2016 63 Stroke - Pipeline by Angion Biomedica Corp, H2 2016 64 Stroke - Pipeline by Antoxis Ltd, H2 2016 65 Stroke - Pipeline by APT Therapeutics, Inc., H2 2016 66 Stroke - Pipeline by ArmaGen Inc, H2 2016 67 Stroke - Pipeline by Asterias Biotherapeutics, Inc., H2 2016 68 Stroke - Pipeline by AstraZeneca Plc, H2 2016 69 Stroke - Pipeline by Athersys Inc, H2 2016 70 Stroke - Pipeline by Bayer AG, H2 2016 71 Stroke - Pipeline by Bioasis Technologies Inc, H2 2016 72 Stroke - Pipeline by Biogen Inc, H2 2016 73 Stroke - Pipeline by Boehringer Ingelheim GmbH, H2 2016 74 Stroke - Pipeline by Cardax Inc, H2 2016 75 Stroke - Pipeline by Cellular Biomedicine Group Inc, H2 2016 76 Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 77 Stroke - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 78 Stroke - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 79 Stroke - Pipeline by D-Pharm Ltd, H2 2016 80 Stroke - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 81 Stroke - Pipeline by DiaMedica Inc, H2 2016 82 Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 83 Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 84 Stroke - Pipeline by Fina Biotech, H2 2016 85 Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 86 Stroke - Pipeline by Glialogix Inc, H2 2016 87 Stroke - Pipeline by Glucox Biotech AB, H2 2016 88 Stroke - Pipeline by Green Cross Corp, H2 2016 89 Stroke - Pipeline by Huons Co Ltd, H2 2016 90 Stroke - Pipeline by International Stem Cell Corp, H2 2016 91 Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 92 Stroke - Pipeline by JN-International Medical Corp, H2 2016 93 Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 94 Stroke - Pipeline by LegoChem Biosciences Inc, H2 2016 95 Stroke - Pipeline by Les Laboratoires Servier SAS, H2 2016 96 Stroke - Pipeline by Living Cell Technologies Ltd, H2 2016 97 Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H2 2016 98 Stroke - Pipeline by M et P Pharma AG, H2 2016 99 Stroke - Pipeline by Magnus Life Ltd, H2 2016 100 Stroke - Pipeline by Mapreg SAS, H2 2016 101 Stroke - Pipeline by Mast Therapeutics Inc, H2 2016 102 Stroke - Pipeline by Medestea Research & Production SpA, H2 2016 103 Stroke - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 104 Stroke - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 105 Stroke - Pipeline by Neuralstem Inc, H2 2016 106 Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 107 Stroke - Pipeline by Neurofx Inc, H2 2016 108 Stroke - Pipeline by Neuronax SAS, H2 2016 109 Stroke - Pipeline by Neurotec Pharma SL, H2 2016 110 Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2016 111 Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H2 2016 112 Stroke - Pipeline by New World Laboratories Inc, H2 2016 113 Stroke - Pipeline by NoNO Inc, H2 2016 114 Stroke - Pipeline by NuvOx Pharma LLC, H2 2016 115 Stroke - Pipeline by Omeros Corp, H2 2016 116 Stroke - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 117 Stroke - Pipeline by PharmatrophiX, Inc., H2 2016 118 Stroke - Pipeline by Pharmaxis Ltd, H2 2016 119 Stroke - Pipeline by Pharmicell Co Ltd, H2 2016 120 Stroke - Pipeline by Phoenix Biotechnology Inc, H2 2016 121 Stroke - Pipeline by Phylogica Ltd, H2 2016 122 Stroke - Pipeline by PhytoHealth Corp, H2 2016 123 Stroke - Pipeline by Pluristem Therapeutics Inc, H2 2016 124 Stroke - Pipeline by Primary Peptides, Inc., H2 2016 125 Stroke - Pipeline by Q Therapeutics Inc, H2 2016 126 Stroke - Pipeline by QR Pharma Inc, H2 2016 127 Stroke - Pipeline by ReCyte Therapeutics Inc, H2 2016 128 Stroke - Pipeline by Regenera Pharma Ltd, H2 2016 129 Stroke - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016 130 Stroke - Pipeline by Remedy Pharmaceuticals Inc, H2 2016 131 Stroke - Pipeline by ReNeuron Group Plc, H2 2016 132 Stroke - Pipeline by SanBio Inc, H2 2016 133 Stroke - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 134 Stroke - Pipeline by Shin Poong PharmCo Ltd, H2 2016 135 Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2016 136 Stroke - Pipeline by Stemedica Cell Technologies Inc, H2 2016 137 Stroke - Pipeline by SynZyme Technologies LLC, H2 2016 138 Stroke - Pipeline by Targazyme Inc, H2 2016 139 Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 140 Stroke - Pipeline by TikoMed AB, H2 2016 141 Stroke - Pipeline by vasopharm GmbH, H2 2016 142 Stroke - Pipeline by Verseon Corp, H2 2016 143 Stroke - Pipeline by Vicore Pharma AB, H2 2016 144 Stroke - Pipeline by Virogenomics BioDevelopment Inc, H2 2016 145 Stroke - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2016 146 Stroke - Pipeline by Zocere Inc, H2 2016 147 Assessment by Monotherapy Products, H2 2016 148 Number of Products by Stage and Target, H2 2016 150 Number of Products by Stage and Mechanism of Action, H2 2016 156 Number of Products by Stage and Route of Administration, H2 2016 162 Number of Products by Stage and Molecule Type, H2 2016 164 Stroke - Dormant Projects, H2 2016 486 Stroke - Dormant Projects (Contd..1), H2 2016 487 Stroke - Dormant Projects (Contd..2), H2 2016 488 Stroke - Dormant Projects (Contd..3), H2 2016 489 Stroke - Dormant Projects (Contd..4), H2 2016 490 Stroke - Dormant Projects (Contd..5), H2 2016 491 Stroke - Dormant Projects (Contd..6), H2 2016 492 Stroke - Dormant Projects (Contd..7), H2 2016 493 Stroke - Dormant Projects (Contd..8), H2 2016 494 Stroke - Dormant Projects (Contd..9), H2 2016 495 Stroke - Dormant Projects (Contd..10), H2 2016 496 Stroke - Dormant Projects (Contd..11), H2 2016 497 Stroke - Dormant Projects (Contd..12), H2 2016 498 Stroke - Dormant Projects (Contd..13), H2 2016 499 Stroke - Dormant Projects (Contd..14), H2 2016 500 Stroke - Discontinued Products, H2 2016 501 Stroke - Discontinued Products (Contd..1), H2 2016 502 Stroke - Discontinued Products (Contd..2), H2 2016 503 Stroke - Discontinued Products (Contd..3), H2 2016 504
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
